For women with tumours harbouring a POLE mutation, 10-year CSS was 100%, in contrast to 96.2% for no specific molecular profile, 84.8% for MSI and 62.3% for p53-mutant tumours (p < 0.001). Here, TP53 is linked to neoplasm.